Company: DVAX
Filing Date: 2025-04-15
Form Type: PRER14A
Source: 0000930413-25-001254
Chunk: 53

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-15
Form: PRER14A
Chunk 53
---
, and that appropriate responses are provided to stockholders in a timely manner. Stockholders may communicate with
our Board by directing comments, concerns, and questions to the Corporate Secretary at Dynavax Technologies Corporation, 2100
Powell Street, Suite 720, Emeryville, California 94608. Stockholders may also communicate with our Board as a group through our
website at https://investors.dynavax.com/corporate-governance/contact-the-board.

Communications will be distributed to the Board, or to any individual directors as appropriate, depending
on the nature or subject matter of the stockholder communication. In that regard, our Board has requested that certain items that
are unrelated to the duties and responsibilities of the Board be filtered, including product complaints or inquiries, new product
suggestions, résumés and other forms of job inquiries, surveys, or business solicitations or advertisements. In
addition, material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the provision that
any communication that is filtered out must be made available to any non-employee director upon request. All communications directed
to the Audit Committee in accordance with our whistleblower policy that relate to questionable accounting or auditing matters
involving the Company will be promptly and directly forwarded to the chairperson of the Audit Committee.

| 37 |

<div align='center'>PROPOSAL 2

ADVISORY VOTE ON EXECUTIVE COMPENSATION</div>

Under the Dodd-Frank Wall Street Reform and Consumer Protection Act and Section 14A of the Exchange Act of
1934, Dynavax stockholders are being asked to approve, on an advisory basis, the compensation of our named executive officers
as disclosed in this proxy statement, which is commonly referred to as a “say-on-pay vote.” This vote is not intended
to address any specific item of compensation, but rather the overall compensation of our named executive officers, which results
from our compensation philosophy, policies and practices as discussed in this proxy statement. The compensation of our named executive
officers subject to the say-on-pay vote is described in the Compensation Discussion and Analysis, the accompanying tables, and
the related narrative disclosure contained in this proxy statement.

Our Compensation Committee is responsible for designing and administering our executive compensation programs.
Our Compensation Committee firmly believes that Dynavax’s executive compensation programs should reward our named executive
officers for performance, and that when key performance objectives are not achieved, the compensation of our named executive officers